Evidence map›Paper›PMID 39397956›Full record

ArticleHeliyon2024

Prognostic modeling and Emerging therapeutic targets Unveiled through single-cell sequencing in esophageal squamous Cell carcinoma.

Binyang Pan, Haochun Shi, Guangyao Shan, Gujie Wu, Kungeng Rao, Jiaqi Liang, Xing Jin, Guoshu Bi, Mengnan Zhao, Weigang Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Binyang PanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Haochun ShiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Guangyao ShanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Gujie WuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Kungeng RaoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Jiaqi LiangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Xing JinDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Guoshu BiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Mengnan ZhaoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Weigang GuoDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ESCC presents a significant global health challenge due to its high mortality rates and varying responses to treatment. This underscores the critical need for novel diagnostic and predictive biomarkers to improve treatment outcomes. Initially, we conducted single-cell transcriptome sequencing on a total of 128,688 cells obtained from 10 patients as part of our research. Utilizing machine learning and cross-validation techniques, we developed a model incorporating 12 genes that distinguish malignant cells from non-malignant ones. In vitro, we explored the effects of IGFBP2 knockdown on the proliferation, invasion, and migration of ESCC cells. The clinical relevance of IGFBP2 was confirmed through IHC and Kaplan-Meier survival analyses. Furthermore, using bioinformatics tools such as GSVA and xCell on public databases, we discovered that high expression of IGFBP2 is associated with an immunosuppressive tumor microenvironment in ESCC, characterized by reduced CD8

Indexed as

Esophageal squamous cell carcinomaImmunotherapySingle-cell RNA sequencingTumor microenvironment

Identifiers

PMID39397956
PMCPMC11470424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.